Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes. Leading Biosciences became Palisades Bio on their listing to Nasdaq.
CUBT has 4 drug license. They only had 1. Potential here.
https://curativebiotech.com/corporate-overview
Slide 15. Bullet #2
https://curativebiotech.com/wp-content/uploads/2021/11/Curative-Biotech-Deck-NonCon-21-15.jpg
“Significantly higher level of COVID-19 neutralizing antibodies in animal models (5 times higher than Moderna vaccine and dozens of times higher than other currently available vaccines)”
That is a bold statement to make unless backed by evidence. If this is true, which I would expect them to not expose themselves to liability then we are about to experience something epic possibly unfold.
My pleasure.
My thought is Richard must have presented Silvestre Law group to Paul. And Paul approved of that relationship moving forward. He must have liked the pitch and potential of M&A exposure and networking.
CUBT broad licensing will eventually be very attractive to a big time player.
On the DD side. We need to find where M-A-B-T completed that animal study to make the statement Covid vaccine 5x antibodies more than Moderna. No references on Investor Presentation.
CEO Richard Garr and Catherine Sohn were former executives of Neuralstem.
https://pitchbook.com/profiles/company/42068-53#overview
Silvestre Law Group was Legal Advisor of M&A of Seneca Biopharm
Seneca Biopharm formerly known as Neuralstem. Acquired/Merged
Acquirer
Leading BioSciences
Hope they seize on Omicron news. It’s primed for an explosive PR
Administrative warnings don’t understand M-A-B-T is $CUBT lol
Nice commentary. That arrest pic is from years ago. Probably a night on the town in 6th street Austin TX. If you haven’t been you wouldn’t know. If you have been to 6th street then you do know lol.
Not too happy with Hans performance either. Where the link showing he is no longer the Director?
There are 3 PRV’s
Due to timeline.
The organic growth of SP probably doesn’t meet with their timeline.
I’m sure they have a date already in mind regardless of SP based off of their timeline and phases of advancing their portfolio.
Guys, we need to find the Dublin Ireland or Amsterdam Netherlands lab or company that CUBT is working with to make the CD-56 antibody.
They have not PR it and Richard said it in DanSfera interview
I searched clinical trials gov website and published literature…. Nothing
We are good. That’s a College of Pharmacy not Pharmacology and they have interest in natural medicines.
The derivative from Indian curry is what they are looking into. Zero animal studies and no intent for human clinical trials. Projected timeline is next 10-15 years.
Dr Dimitrov CD-56 antibody is look great.
Facebook bro?! SMH
Come on man.
CUBT looking for a strong finish for the year.
Provide me the link of the study or published literature and I’ll tell you.
Definitely
Andrew De Angelo is on BoD!
If Richard Garr hasn’t played the OTC pump PR game then he definitely isn’t going to bend to bashing on message boards.
Imo a Principal Investigator for the first drug program filing will be named.
The process of how the meeting/document was released does irk me but the language and ratio are standard legal terms that other companies use as well. It simply authorizes that between now and April 2023.
Will the RS? It’s likely.
When? You don’t know that.
2 options based on beliefs since facts are limited.
1. You believe the company is garbage and the portfolio is worthless…. Sell before the RS, Hold for the RS and they dilute the worthless shares.
Or
2. You believe the company and its portfolio of drugs have value… Sell before the RS, buy back the dip or after the RS. Or Hold and buy the dip and believe they have the ability to bring in institutions and we ride
This will run after the dip is bought up….. nothing changes. I doubt they RS from 10 cents.
This will get to 50 cents before considering that imo. I think they will see the effects of the first IND.
My thoughts exactly. Read my last sentence on my post.
Possibly institutions lining up.
Exactly! Larry likes to gives buying signals. At least that’s how I take them.
Thoughts?
If insiders (company buyers / subsidiary buyers) bought Friday as reported on 8-K would that imply that they have some general knowledge that a reverse split is unlikely?
Wouldn’t it be bad to buy shares then Larry turn around and R/S them? Or if they had general knowledge of institutions lining up.
VERDOSA means Beautiful Green
It’s from the two Spanish words VERDe (Green) + hermOSA (Beautiful)
DD Challenge.
Anyone find anything on Dublin or Amsterdam companies that may be producing the CD56 antibodies stated in Garr’s interview?
I’ll be looking
4 Drug Programs consisting of 3 PRV’s and 1 Orphan Drug Designation
1. Rabies - IMT504 : Orphan Drug Designation, PRV for Tropical Disease
2. Glioblastoma - CD56 Antibody : PRV for Rare Pediatrics
3. Eye Disease - Metformin : Expedited 502b pathway, PRV for Stargardts Rare Pediatrics
4. Covid-19 - Recombinant Protein Vaccine with IMT504 : Operation Warp Speed
“metformin” is the active ingredient
Don’t forget Garr said Gen 2… meaning they plan to acquire more assets to add to the current 4 drug programs
Here is a comparison of a similar Recombinant Protein Covid 19 Vaccine so everyone (robots in included) can have an idea of timelines.
Vaccines can take up to 10 years to go through a trial pipeline.
However under Operation Warp Speed (defense authorization/pandemic) the vaccines moving quickly.
Comparison Sanofi/COVID-19 Vaccine similar to our by mechanism
Q1 March 2020 - Announce CV-19 vaccine intent
Q3 September 2020 - Initiate Phase 1/2
Q1 February 2021 - Initiate Phase 2
Q2 May 2021 - Initiate Phase 3 / In Progress
https://www.sanofi.com/en/our-covid-19-vaccine-candidates
Your are free to buy and sell when you want.
I’m buying and holding for hopefully all 4 programs are filed
February 04, 2021 Paul Michaels - The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.
Tell me what Paul Michael’s said in February?
It’s not that I don’t care. I’m just comfortable being uncomfortable investing in OTC’s. It’s not for the weak hearted.
One thing I do see is Chairman Paul Michael’s was more accurate in his statement of saying in human trials by Q32022. And he said that back in February… re read the statements
CEO Interview was insightful. Appreciate DanSfera team providing these. Cut out the robotic noise.
https://stocktwits.com/Austero/message/392729994
Summarized here:
IND of reformulated Metformin Q12022, human clinical trials Q32022, completion of human clinical trials Q42022 (to me this means Phase 1 or Phase 2)
Retweets remain private. Why don’t you copy and paste what they are tweeting about Medh here?
What you believe versus evidence are 2 separate things.
I’m on your side on transparency. I would have rather the dilution end before all those acquisition catalyst came out. But more shareholders are now in Medh and we will muscle through the wall.
Only positive is Board of Directors look legit and would not risk reputation. I’m sure at that level they also vet and background check the owner inviting them.
He’s only (if true) ripping MEDH to his private followers, not publicly
This is our vaccine company now. Nidovax (subsidiary of MidAtlantic Bio Therapeutics).
https://nidovax.com/
Covid Vaccine organization is tracking developments.
https://covidvax.org/covid19-vaccine/NidoVax/Unknown-IMT504-technology-NidoVax
All coming together
CUBT Covid-19 vaccine “adjuvant” vaccine is relevant.
Study cited in PR https://www.medrxiv.org/content/10.1101/2021.09.13.21263535v1
Target population: 10% of the population worldwide is affected by chronic kidney disease (CKD). 2-20 million receive/need dialysis.
Nephrology Consultants and Kidney organizations will support effort (imo).
Add and Hold on to your shares!
Eagle/Threeflight/Algorithm/CurbOnTheGo …. You guys still here? Any chatter out there?
Details within the Details.
Don’t matter, 2022 is our year!
https://stocktwits.com/Austero/message/378934828
Next 60 days will be interesting. Couple things to track:
- 10Q filing on or near Aug. 13th
- 2nd Clinic open end of Aug. or first of Sept.
I’d like to see an update on Denver. Simply that hiring a NP has taken place.
The waiting is the hardest but we did the same last year. July 2020 it ran to 0.08 then fell back to 0.02… waited for 6 month and watched it run > 2,000%
My primary reason to go long term is the all star executive here.
It’s called a “deal” iRobber
Not all deals and partnerships are created equal.
Look at it this way… CUBT could either not have a deal and have zero or be part of the play and get their cut.